Evidence map›Paper›PMID 38544972›Full record

ArticleJournal of market access & health policy2024

An Inclusive Civil Society Dialogue for Successful Implementation of the EU HTA Regulation: Call to Action to Ensure Appropriate Involvement of Stakeholders and Collaborators.

Thomas Desmet, Elaine Julian, Walter Van Dyck, Isabelle Huys, Steven Simoens, Rosa Giuliani, Mondher Toumi, Christian Dierks, Juliana Dierks, Antonella Cardone and 12 more

Abstract read
In one paragraph

Article in Journal of market access & health policy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Thomas DesmetHealthcare Management Centre, Vlerick Business School, 1210 Brussels, Belgium.ORCID https://orcid.org/0000-0001-7630-4850
Elaine JulianSecretariat of the European Access Academy (EAA), 4059 Basel, Switzerland.
Walter Van DyckHealthcare Management Centre, Vlerick Business School, 1210 Brussels, Belgium.ORCID https://orcid.org/0000-0002-2829-3779
Isabelle HuysDepartment of Pharmaceutical and Pharmacological Sciences, KU Leuven, 3000 Leuven, Belgium.
Steven SimoensDepartment of Pharmaceutical and Pharmacological Sciences, KU Leuven, 3000 Leuven, Belgium.ORCID https://orcid.org/0000-0002-9512-2005
Rosa GiulianiGuy's and St Thomas' NHS Foundation Trust, London SE1 7EH, UK.
Mondher ToumiPublic Health Department, Faculty of Medicine, Aix-Marseille University, 13002 Marseille, France.ORCID https://orcid.org/0000-0001-7939-7204
Christian DierksDierks+ Company, 10115 Berlin, Germany.
Juliana DierksDierks+ Company, 10115 Berlin, Germany.
Antonella CardoneCancer Patients Europe, 1000 Brussels, Belgium.ORCID https://orcid.org/0000-0003-3685-1512
Francois HouÿezEuropean Organisation for Rare Diseases (EURORDIS), 75014 Paris, France.ORCID https://orcid.org/0000-0002-4202-6001
Mira PavlovicMedicines Development and Training (MDT) Services, 75020 Paris, France.
Michael BerntgenEuropean Medicines Agency (EMA), 1083 HS Amsterdam, The Netherlands.
Peter MolDepartment of Clinical Pharmacy and Pharmacology, University Medical Center Groningen (UMCG), University of Groningen, 9713 GZ Groningen, The Netherlands.ORCID https://orcid.org/0000-0002-4262-3180
Anja SchielNorwegian Medicines Agency (NOMA), 0950 Oslo, Norway.ORCID https://orcid.org/0000-0002-1258-4731
Wim GoettschUtrecht Centre for Pharmaceutical Policy, Division of Pharmacoepidemiology and Clinical Pharmacology, University of Utrecht, 3584 CS Utrecht, The Netherlands.ORCID https://orcid.org/0000-0002-8022-7496
Fabrizio GianfrateDepartment of Economics and Management, University of Ferrara, 44121 Ferrara, Italy.ORCID https://orcid.org/0000-0003-0513-0894
Stefano CapriSchool of Economics and Management, Cattaneo-LIUC University, 21053 Castallanza, Italy.ORCID https://orcid.org/0000-0003-4633-4420
James RyanAstra Zeneca, Cambridge CB2 8PA, UK.
Pierre DucournauAbbvie AG, 6330 Cham, Switzerland.
Oriol Solà-MoralesHiTT Foundation, International University of Catalonia-UIC, 08015 Barcelona, Spain.ORCID https://orcid.org/0000-0002-8312-8178
Jörg RuofSecretariat of the European Access Academy (EAA), 4059 Basel, Switzerland.ORCID https://orcid.org/0000-0001-8706-934X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesStakeholder involvement has long been considered a success factor for a joint European health technology assessment (HTA) process, and its relevance is now anchored in the EU HTA Regulation's (EU HTAR) legislative wording. Therefore, we aimed to explore the roles, challenges, and most important activities to increase the level of involvement per stakeholder group.

methodsAt the 2022 Fall Convention of the European Access Academy (EAA), working groups addressed the involvement of patients, clinicians, regulators, health technology developers (HTD), and national HTA bodies and payers within the EU HTA process. Each working group revisited the pre-convention survey results, determined key role characteristics for each stakeholder, and agreed on the most important activities to fulfill the role profile. Finally, the activities suggested per group were prioritized by plenary group.

resultsThe prioritized actions for patients included training and capacity building, the establishment of a patient involvement committee, and the establishment of a patient unit at the EC secretariat. For clinicians, it included alignment on evidence assessment from a clinical vs. HTA point of view, capacity building, and standardization of processes. The most important actions for regulators are to develop joint regulatory-HTA guidance documents, align processes and interfaces under the regulation, and share discussions on post-licensing evidence generation. HTDs prioritized scientific advice capacity and the review of the scoping process, and further development of the scope of the assessment report fact checks. The top three actions for national HTA bodies and payers included clarification on the early HTD dialogue process, political support and commitment, and clarification on financial support.

conclusionsAddressing the activities identified as the most important for stakeholders/collaborators in the EU HTA process (e.g., in the implementation of the EU HTA Stakeholder Network and of the guidance documents developed by the EUnetHTA 21 consortium) will be key to starting an "

Indexed as

EUHTAhealth policyhealth technology assessmentstakeholder involvement

Identifiers

PMID38544972
PMCPMC10971267

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.